Phospholipase D in brain function and Alzheimer's disease.
Tiago Gil Oliveira1, Gilbert Di Paolo
1Department of Pathology and Cell Biology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.
Biochimica Et Biophysica Acta
|April 20, 2010
Summary
Phospholipids, not just cholesterol, are crucial in Alzheimer's disease (AD). This review highlights phospholipase D's role in AD pathogenesis and brain function.
Area of Science:
- Neuroscience
- Biochemistry
- Lipidomics
Background:
- Alzheimer's disease (AD) is a leading neurodegenerative disorder.
- The role of lipids, particularly phospholipids, in AD pathogenesis is under-investigated.
- Cholesterol has been extensively studied, but other lipids warrant attention.
Purpose of the Study:
- To review the link between phospholipase D and normal brain function.
- To summarize evidence connecting phospholipase D to Alzheimer's disease.
- To emphasize phospholipase D's role in beta-amyloid signaling and amyloid precursor protein processing.
Main Methods:
- Literature review synthesizing current research.
- Analysis of studies on phospholipase D in neurological contexts.
- Examination of evidence linking lipid metabolism to AD pathology.
Main Results:
- Phospholipase D, an enzyme synthesizing phosphatidic acid, is implicated in brain function.
- Evidence suggests phospholipase D plays a significant role in Alzheimer's disease.
- The enzyme is involved in signaling pathways affected by beta-amyloid.
Conclusions:
- Phospholipase D is a key enzyme linking lipid metabolism to Alzheimer's disease.
- Understanding phospholipase D's function is critical for AD research.
- Targeting phospholipase D may offer new therapeutic avenues for AD.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:03Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Calcium Ion Concentration Mechanism
If over time, all...